Evidence map›Paper›PMID 37115598›Full record

ArticleJMIR formative research2023

A New Digital Health Program for Patients With Inflammatory Bowel Disease: Preliminary Program Evaluation.

Saemundur Jon Oddsson, Thrudur Gunnarsdottir, Lilja Gudrun Johannsdottir, Maria Lovisa Amundadottir, Arna Frimannsdottir, Pauliina Molander, Anna Karoliina Ylanne, Anna Sigridur Islind, Maria Oskarsdottir, Tryggvi Thorgeirsson

Open access · goldAbstract read
In one paragraph

Article in JMIR formative research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Saemundur Jon OddssonSidekick Health Digital Therapeutics, Reykjavik, Iceland.ORCID https://orcid.org/0000-0001-9427-443X
Thrudur GunnarsdottirSidekick Health Digital Therapeutics, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-2419-8846
Lilja Gudrun JohannsdottirReykjavik University, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-2076-3289
Maria Lovisa AmundadottirSidekick Health Digital Therapeutics, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-6066-6600
Arna FrimannsdottirGallup, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-0196-8406
Pauliina MolanderAbdominal Center, Gastroenterology, Helsinki University Hospital, Helsinki, Finland.ORCID https://orcid.org/0000-0002-9494-3573
Anna Karoliina YlanneSidekick Health Digital Therapeutics, Reykjavik, Iceland.ORCID https://orcid.org/0000-0003-4808-607X
Anna Sigridur IslindReykjavik University, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-4563-0001
Maria OskarsdottirReykjavik University, Reykjavik, Iceland.ORCID https://orcid.org/0000-0001-5095-5356
Tryggvi ThorgeirssonSidekick Health Digital Therapeutics, Reykjavik, Iceland.ORCID https://orcid.org/0000-0003-4963-6424
Reykjavík University · ISReykjavík Energy (Iceland) · ISUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) causes chronic inflammation of the gastrointestinal tract. IBD is characterized by an unpredictable disease course that varies greatly between individuals and alternates between the periods of relapse and remission. A low energy level (fatigue) is a common symptom, whereas stress and reduced sleep quality may be the triggering factors. Therapeutic guidelines call for effective disease assessment, early intervention, and personalized care using a treat-to-target approach, which may be difficult to achieve through typical time- and resource-constrained standard care. Providing patients with a digital health program that incorporates helpful self-management features and patient support to complement standard care may be optimal for improving the disease course.

objectiveThis study aimed to perform a preliminary program evaluation, analyzing engagement and preliminary effectiveness and the effect on participants' energy levels (fatigue), stress, and sleep quality, of a newly developed 16-week digital health program (SK-311 and SK-321) for patients with IBD.

methodsAdults with IBD were recruited to participate in a real-world, live, digital health program via Finnish IBD patient association websites and social media. No inclusion or exclusion criteria were applied for this study. Baseline characteristics were entered by the participants upon sign-up. Platform engagement was measured by tracking the participants' event logs. The outcome measures of stress, energy levels (fatigue), and quality of sleep were reported by participants through the platform.

resultsOf the 444 adults who registered for the digital health program, 205 (46.2%) were included in the intention-to-treat sample. The intention-to-treat participants logged events on average 41 times per week (5.9 times per day) during the weeks in which they were active on the digital platform. More women than men participated in the intervention (126/205, 88.7%). The mean age of the participants was 40.3 (SD 11.5) years, and their mean BMI was 27.9 (SD 6.0) kg/m

conclusionsThese results support the feasibility of a digital health program for patients with IBD (SK-311 and SK-321) and suggest that treatment completion might have a substantial positive effect on patient-reported stress and energy levels in a real-world setting. These findings are promising and provide initial support for using the Sidekick Health digital health program to supplement standard care for patients with IBD.

Indexed as

digital platformdigital therapeuticsfatigueinflammatory bowel diseasemobile phonereal-world evidenceself-managementsleepstress

Identifiers

PMID37115598
PMCPMC10182451
OpenAlexW4322711772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.